- Home
- ACRS vs FCAP Comparison
ACRS vs FCAP Comparison
Compare ACRS & FCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- FCAP
- Stock Information
- Founded
- ACRS 2012
- FCAP 1891
- Country
- ACRS United States
- FCAP United States
- Employees
- ACRS N/A
- FCAP N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- FCAP Savings Institutions
- Sector
- ACRS Health Care
- FCAP Finance
- Exchange
- ACRS Nasdaq
- FCAP Nasdaq
- Market Cap
- ACRS 165.7M
- FCAP 161.2M
- IPO Year
- ACRS 2015
- FCAP 1999
- Fundamental
- Price
- ACRS $1.59
- FCAP $43.07
- Analyst Decision
- ACRS Strong Buy
- FCAP
- Analyst Count
- ACRS 9
- FCAP 0
- Target Price
- ACRS $9.25
- FCAP N/A
- AVG Volume (30 Days)
- ACRS 1.3M
- FCAP 31.5K
- Earning Date
- ACRS 08-06-2025
- FCAP 07-25-2025
- Dividend Yield
- ACRS N/A
- FCAP 2.65%
- EPS Growth
- ACRS N/A
- FCAP 2.61
- EPS
- ACRS N/A
- FCAP 3.65
- Revenue
- ACRS $17,777,000.00
- FCAP $42,869,000.00
- Revenue This Year
- ACRS N/A
- FCAP N/A
- Revenue Next Year
- ACRS $11.77
- FCAP N/A
- P/E Ratio
- ACRS N/A
- FCAP $11.98
- Revenue Growth
- ACRS N/A
- FCAP 6.35
- 52 Week Low
- ACRS $1.05
- FCAP $28.50
- 52 Week High
- ACRS $5.17
- FCAP $53.85
- Technical
- Relative Strength Index (RSI)
- ACRS 59.88
- FCAP 49.16
- Support Level
- ACRS $1.44
- FCAP $42.70
- Resistance Level
- ACRS $1.52
- FCAP $44.23
- Average True Range (ATR)
- ACRS 0.10
- FCAP 1.69
- MACD
- ACRS 0.00
- FCAP 0.22
- Stochastic Oscillator
- ACRS 79.17
- FCAP 79.82
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.